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1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that gradually leads to
severe cognitive impairment. The neuropathological hallmarks of AD include beta-amyloid
plaques, tau neurofibrillary tangles, inflammation and glial responses, vascular dysfunction,
synapse loss and cholinergic neurodegeneration. Currently, the diagnosis of possible or
probable AD is based on a time consuming combination of clinical and psychological testing,
imaging, and the analysis of three well-established biomarkers (beta-amyloid(42), total tau and
phospho-tau-181) in cerebrospinal fluid. The search for biomarkers in blood is of high
importance to avoid invasive lumbar puncture and to allow fast and easy analysis of a high
number of patients. Biomarkers have been screened in blood of AD patients in plasma/serum,
peripheral blood mononuclear cells (PBMCs), monocytes or also in platelets.
Platelets are interesting targets to study AD because they share some properties with neurons:
they contain the neurotransmitter serotonin and the amyloid-precursor protein (APP), which
produces the beta-amyloid, which aggregates in the brain of AD patients. Moreover, platelets
are an easily accessible source of human cells. This review focuses on changes in the platelets
of AD patients and will summarize (1) platelet activation including mean platelet volume,
membrane fluidity and coated platelets, (2) serotonin metabolism, (3) APP isoforms and
processing enzymes, including secretases, (4) oxidative stress and radicals, including nitric
oxide metabolism and mitochondrial pathologies, including cytochrome-c oxidase and
monoamino-oxidase-B and (5) enzymatic activity, such as glycogen synthase kinase-3 or
phospholipase A2. In spite of all efforts, the discrepant results so far have prevented the
establishment of a valid platelet-derived AD biomarker. With this survey we provide a detailed
review about the major current findings on the potential use of platelet markers in AD.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by
progressive deterioration in cognition leading to premature death. The neuropathological
hallmarks of AD include beta-amyloid (Aβ) plaques, neurofibrillary tau tangles, inflammation
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and glial responses, synapse loss and cholinergic neurodegeneration among others. The
worldwide prevalence of dementia was estimated as high as 24.2 million by 2005 and is
expected to quadruplicate by 2050 [1, 2]. North America and Western Europe show the highest
prevalence rate of dementia for persons >60 years [3]. Most dementia cases (70%) are attributed
to AD, placing a considerable burden on society [2]. The increasing rate of AD cases not only
stresses the establishment of efficient therapeutic intervention but also the identification of
economic and reliable biomarkers. In both domains great efforts and smaller progress have
been made in the last decades, while the desired breakthrough has yet to be awaited.
AD is classified into clinically indistinguishable early onset genetic AD (onset < 60 years) and
late onset sporadic AD (> 60 years). Early onset AD accounts for approx. 1-5% of all cases and
is associated with a more rapid progression of the neurodegenerative process and autosomal
dominantly inherited mutations with a high penetrance. Sporadic AD accounts for >95% of all
dementia cases and turned out to be a more heterogeneous disease. Currently, the diagnosis
of possible or probable AD according to the NINCDS-ADRDA criteria is based on a time
consuming combination of psychological testing, imaging, and the analysis of three well-
established biomarkers (beta-amyloid(42), total tau and phospho-tau-181) in cerebrospinal
fluid (CSF).
Biochemical markers mirror the physiological changes and can be objectively measured and
evaluated as an indicator of pathological changes. A good biomarker must be sufficiently
sensitive to detect early changes and specific to differentiate AD from clinically similar
conditions. Besides high diagnostic and prognostic accuracy, biomarkers should allow global
reproducibility with non-invasive and easy-to-perform tests. Within the search for peripheral
AD-specific biomarkers, anucleated blood platelets have shown to be a promising target, since
they represent the principal component of human blood affected by (early) biochemical
alterations during AD. Moreover, platelets are an easily accessible source of human tissue and
contain proteins found in neuronal cells.
In this chapter we aim to review changes in AD occurring in platelets to understand whether
they may have a potential as putative biomarkers for diagnosing AD. We will focus on (1)
platelet activation including mean platelet volume, membrane fluidity and coated platelets,
(2) serotonin metabolism, (3) APP isoforms and processing enzymes, including secretases, (4)
oxidative stress and radicals, including nitric oxide metabolism and mitochondrial patholo‐
gies, including cytochrome-c oxidase and monoamino-oxidase-B activity and (5) enzymatic
activity, such as glycogen synthase kinase-3 or phospholipase A2. In spite of all efforts made,
the discrepant results so far have prevented the establishment of a valid platelet-derived AD
biomarker. With this survey we provide a detailed review about the major current findings on
the potential use of platelet markers in AD.
2. Platelet activation
Vascular risk factors were traditionally considered to distinguish between vascular dementia
and AD. However, in the last decade a series of studies revealed that vascular events are
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involved in the development of AD and the arbitrary classification into vascular dementia and
AD is very much outdated [4-7]. Several studies reported vascular alterations such as an
increased number of fragmented vessels, atrophic string vessels, changed vessel diameters,
altered capillary membrane and collagen accumulation in the basement membrane of AD
patients [8, 9]. Besides, deposits of Aβ in cerebral vessels (cerebral amyloid angiopathy (CAA))
induce severe damage of the vessel wall and alter the cerebral blood flow promoting the
progression of AD [10]. Moreover, it became clear that AD associated alterations are not solely
limited to the brain and occur in vessels and blood cells of the peripheral system [11].
Activation and aggregation of platelets are important steps for haemostasis at sites of vascular
injury, while uncontrolled activation can trigger thrombotic vessel occlusion at sides of
atherosclerotic plaque rupture [12] and lead to chronic inflammatory reactions. In AD,
activated platelets are strongly linked to vascular processes and are proposed to be the missing
link for the association between atherosclerotic events and AD [13]. Adhesion and activation
of platelets on the vascular wall progressively lead to vascular inflammation and atheroscle‐
rosis, thus playing a key role in the development of AD-associated conditions. Increased
platelet activation has been identified in the late 90s, due to damaged cerebral endothelial cells
or membrane abnormalities in the AD brain [14].
Moreover, increased platelet activation, measured by GPIIb-IIIa complex activation or P-
selectin expression is significantly higher in AD patients with fast cognitive decline compared
to slow cognitive decline [13]. Furthermore it is known, that peripheral Aβ peptides contribute
to platelet adhesion and activation in the initiation of thrombus formation [15, 16]. Recently it
has been shown that activated platelets aggregate at sites of vascular Aβ promoting CAA by
inducing platelet thrombus formation leading to vessel occlusion at vascular Aβ plaques [17,
18]. Because platelets are major players in blood flow alterations and vascular diseases, it was
suggested that they do not only mirror AD related changes, but promote actively the progres‐
sion of AD. In light of these findings it is conceivable that increased platelet activity could
induce the progression of AD by contributing to peripheral vascular damage and endothelial
senescence. Uncontrolled activation of platelets in AD-subjects may result in chronic inflam‐
mation mediating endothelial cell stress, which, in turn, may trigger platelet activation [19].
Alternatively, systemic inflammation in AD patients may result in platelet activation creating
a vicious, self-amplifying circle [20]. Thus, it is conceivable that activated platelets contribute
at different sites to the progression of AD.
References Effect on platelet activation
Sevush et al., 1998 ↑  in AD
Stellos et al., 2010, 2014
↑  in AD with faster cognitive decline compared to AD with
slow decline
↑  in coronary artery disease with cognitive impairment
Table 1. Platelet activation in AD
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2.1. Effects on platelet volume
The platelet volume is a marker of platelet activation and thus involved in the pathophysiology
of multiple pro-inflammatory diseases. Along with platelet activation, platelet volume values
are considered indicators for vascular events linked to cerebral vascular dementia. In AD, both
increased [21, 22] and decreased [23, 24] mean platelet volume has been reported. These
heterogeneous results point out the importance of establishing methodological consensus in
the isolation and processing of platelets, since they are very sensitive to cellular damage.
References Effect on platelet volume
Yagi et al., 1984 ↑  in vascular dementia compared to AD
Yesil et al., 2012 ↑  in AD
Wang et al., 2013 ↓  in AD and MCI; associated with MMSE
Liang et al., 2013 ↓  in vascular dementia and AD
Table 2. Platelet volume in AD
2.2. Effects on membrane fluidity
Discrepant results have been published concerning platelet membrane fluidity: while de‐
creased fluidity of cell membranes from platelets is associated with normal ageing, increased
internal membrane fluidity is one of the first alterations to be reported in platelets [25, 26].
Increased platelet membrane fluidity becomes apparent by a decrease in the fluorescence
anisotropy of 1,6-diphenyl-1,3,5-hexatriene (DPH) in labelled membranes. It was proposed,
that this apparent abnormality of membranes in AD patients is due to an increase in internal
membranes [26]. However, no significant differences in either cholesterol or phospholipid
compared to healthy subjects has been observed [26], while an increase of intracellular platelet
membranes in AD patients has been reported [27]. Other findings suggest furthermore that
demented patients with increased platelet membrane fluidity display an earlier onset and a
more rapid deterioration of cognitive symptoms compared to other demented subjects [25]. In
light of these findings, platelet membrane fluidity was proposed as a biological risk factor for
AD, since it is associated with significant contributions to the risk of developing AD [28, 29].
However, others failed to demonstrate differences in platelet membrane fluidity between AD
patients and healthy controls, concluding that platelet membrane fluidity cannot be considered
as antemortem biomarker for AD [30-32]. An increase in DPH fluorescence anisotropy has
been reported [33-36] and as anisotropy is inversely related to membrane fluidity, these results
indicate in contrast to the previously mentioned studies a decrease of the external and internal
membrane fluidity in AD [33]. It was suggested that the short life span of platelets makes them
less susceptible for long-term modifications. And finally, a reduced fluidity in the platelet inner
mitochondrial membrane has been reported, which was associated with oxidative damage
[37], while others correlated membrane fluidity with alterations of APP fragments [38].
The Non-Thrombotic Role of Platelets in Health and Disease194
References Effects on membrane fluidity
Zubenko et al., 1987, 1990 ↑  in familial AD by fluorescence anisotropy
Kozubski et al., 1999, 2002 ↑  in AD with 2 spin-labelled markers
Cohen et al., 1987: Piletz et al.,1991 ↑  by fluorescence anisotropy, ↓  ratio of cholesterol tophospholipid
Kaakkola et al., 1991 ↑  in AD and multi-infarct dementia compared to controls
Ortiz et al., 2008 ↓  fluidity of platelet inner mitochondrial membrane
Fernandes et al., 1999 unchanged in AD by fluorescence anisotropy
Kukull et al., 1992 unchanged
Kálmàn et al., 1994 ↑  in AD by fluorescence anisotropy
Cardoso et al., 2004 unchanged in AD compared to controls
Zainaghi et al., 2007 membrane fluidity correlated with alteration of APPfragments
Vignini et al., 2013 ↓  in AD by fluorescence anisotropy, worse profile for malepatients
Hajimohammadreza et al., 1990 ↑  in AD by fluorescence anisotropy
Table 3. Platelet membrane fluidity in AD
2.3. Coated platelets
Coated-platelets (PLTs) are a subset of platelets produced upon dual-agonist stimulation with
collagen und thrombin retaining several procoagulant α-granule proteins on their surface [39].
PLTs are important for the coagulation cascade because of their ability to generate thrombin
at sites of vascular damage. Effectively, it was suggested that increased levels of PLTs may be
related to prothrombotic conditions [40], while decreased levels of PLTs were linked to an
increased risk for haemorrhage [41]. It was also demonstrated that coated-platelet levels are
elevated in amnestic mild cognitive impairment (MCI) and correlate with the progression of
AD [40, 42-45]. Additionally, the same group showed that MCIs with elevated coated-platelet
levels are more likely to develop AD, while they found no significant alterations in patients
with frontotemporal lobe dementia [44, 45]. So far, coated platelets seem to be an interesting
target, which needs to be reproduced internationally by other research groups.
3. Serotonin
Several studies report abnormalities in serotonin (5-HT) concentration as well as alterations in
its uptake during AD, possibly linked to psychobehavioral problems such as e.g. depression
[46-48]. Platelets accumulate high levels of serotonin in dense granules and release it upon
activation [49]. Early studies failed to demonstrate altered serotonin processing in platelets [50,
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51], while in the early 90s heterogeneous results regarding 5-HT Km (Michaelis-Menten
constant) and maximal velocity (Vmax) binding affinity were published [52, 53, 54]. Compared
to controls, patients with AD demonstrated in different studies significantly lower platelet
serotonin concentrations [55-58]. However, an increased 5-HT concentration in low-density
platelet populations was recently reported [59]. Likewise, heterogeneous results have been
reported for serotonin uptake: both increased and decreased serotonin uptake was found in
AD platelets [52, 60]. In light of these data and despite great efforts, so far platelet-derived
serotonin has not been established as a reliable biomarker for AD.
References Effects on serotonin
Tukiainen et al., 1981 unchanged 5-HT uptake in
Andersson et al., 1991 unchanged maximum number of binding sites (Bmax) and bindingaffinity
Inestrosa et al., 1993 ↓  ability to accumulate 5-HT↓  Km and Vmax
Kumar et al., 1995a ↓  5-HT concentration
Kumar et al., 1995b ↑  affinity of binding of 5-HT to the platelet membrane in AD (onlyfemales tested)
Arora et al., 1991 ↑  Vmax 5-HT-uptake in mild and moderate ADTrend ↓  Vmax 5-HT-uptake in severe AD
Koren et al., 1993 ↓  [3H]-5-HT uptake
Mimica et al., 2008 ↓  5-HT concentrations in non-psychotic female and psychotic maleAD patients compared to controls
Muck-Seler et al., 2009 ↓  5-HT concentrations in the late phase of AD compared to otherphases and controls
Milovanovic et al., 2014 ↑  in low-density platelet populations
Prokselj et al., 2014 ↓  5-HT concentrations in AD compared to AD controls
Vmax = maximum number of 5-HT uptake sites; Km = Michaelis-Menten constant; EOAD = Early Onset AD
Table 4. Platelet 5-HT in AD
4. Amyloid Precursor protein (APP) and secretases
4.1. APP isoforms and ratios
APP is an integral membrane protein with a large extracellular domain and a shorter, intra‐
cellular C-terminal tail. Three major APP isoforms (770, 751 and 695 kDa) have been described.
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APP 751 und APP 770 contain a Kunitz-type serine protease inhibitor domain (APP KPI), while
APP 695 lacks this domain. The APP isoforms are cut by different enzymes (secretases) into
smaller peptides, whereas sequential cleavage by β-secretase (BACE1) and γ-secretase
(ADAM-10) generates the neurotoxic Aβ fragments. Conversely, cleavage by α-secretase
precludes the formation of amyloid fragments by processing APP within the Aβ domain.
Platelets are of particular interest in AD research, because they contain high levels of APP
[61-63]. In contrast to neuronal tissues where isoform 695 lacking the KPI domain is the most
abundant one, platelets express mainly APP770 whereas APP695 is marginally present [64].
Platelets contain α-, β-, γ- secretase activities and generate different APP fragments: sAPPα,
sAPPβ, the amyloidogenic fragment (C99) and Aβ peptides [65, 66]. Platelet APP is mainly
processes by the α-secretase pathway releasing soluble APP (sAPP) [66] and predominantly
Aβ(40). Both APP and Aβ are stored in α-granules of platelets and become released upon
activation by agents like the physiological agonists thrombin and collagen. A recent study
reports significant up-regulation of platelet APP isoforms compared to controls, and a
correlation between APP mRNA levels and cognitive impairment [67]. The same group found
significant up-regulation of platelet mRNA expression level of total APP and APP containing
a KPI domain in patients with AD and frontotemporal lobe dementia compared to controls
[68]. We have recently shown that platelet-secreted APPβ in MCI and AD is significantly
increased when measured with ELISA compared to control subjects, while no changes in
sAPPα are seen [69].
References APP expression and release
Vignini et al., 2013
↑  mRNA of total APP and APP containing KPI domain in
AD and FTLD
↑  APP isoforms compared to controls
Marksteiner and Humpel, 2013 ↑  sAPP–β in MCI and AD compared to controlsunchanged sAPP-α in MCI and AD compared to controls
Table 5. Platelet APP expression in AD
Several studies showed that the platelet APP ratio (defined as the ratio between the upper
130kDa and the lower 106-110kDa isoforms) is significantly lower in AD patients compared
to controls and patients with other forms of dementia [70-77]. It seems that the alteration of
platelet APP isoforms is an early event in AD and the ratio shows to be a consistent predictor
for the conversion from MCI to AD. In fact, MCI subjects converting to AD showed signifi‐
cantly decreased APP ratios at baseline compared to other dementia forms and stable MCI
subjects [78-80]. Furthermore, the APP ratio positively correlates with cognitive decline, i.e.
the lower the ratio, the more severe the disease [38, 73]. Furthermore, it has been shown that
carriers of the APOE4 allele are associated with a larger reduction in the APP ratio [81].
Moreover, administration of acetylcholine esterase inhibitors [82, 83] increases the ratio of APP
forms in AD suggesting a possible effect of these drugs on APP trafficking in platelets. The
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proposed cut-off scores are around 0.56 with a sensitivity of 88% and specificity of 89% [80,
84]. Thus, the APP ratio has been proposed as a potential biomarker in prodromal AD-stages
and a reliable indicator for the disease progress. Despite the promising homogeneous findings
the validity of APP ratio as a useful supportive biomarker for AD diagnosis is not yet inter‐
nationally established. Methodological problems including lack of sensitivity and diversity of
the used antibodies and different isolation procedures of platelets may account for this
problem.
References Effects on APP ratio
Di Luca et al., 1996, 1998 ↓  in AD and elderly patients with Down Syndrom; ratiocorrelated with the severity of the disease
Rosenberg et al., 1997 ↓  in AD compared to controls
Baskin et al., 2000, 2001
↓  specific in AD compared to PD and HS (Hemorrhagic
Stroke);
unchanged in cognitively normal young adults carrying PS-1
mutations
Padovani et al., 2001, 2002 ↓  in MCI and mild and very mild AD
Borroni et al., 2002, 2003, 2004 ↓  in MCIs converting to AD and early stages of probable AD
Liu et al., 2005 ↓  in AD; increases with galantamine treatment for 12 weeks
Tang et al., 2006 ↓  in AD
Zainaghi et al., 2007, 2012 ↓  in MCI converting to dementia upon follow-up
Srisawat et al., 2013 ↓  in Thai patients with AD
Table 6. Platelet APP ratio in AD
4.2. Enzymatic activity: BACE1 and ADAM-10
APP is cleaved into secreted (soluble) APP (sAPP), smaller intracellular fragments and the
Aβ peptides (40, 42 or 43 amino acids) by three secretases (α, β, γ). The α-secretase leads to the
non-amyloidogenic pathway, while cleavage of APP by β -secretase (BACE1) and γ-secretase
(ADAM-10) generates the toxic Aβ fragments. So far, several authors report increased BACE1
in AD by Western blotting or ELISA analysis [69, 73, 85, 86]. However, using a novel ELISA
system a significant decrease of BACE1 N-terminal and C-terminal fragments has been
reported in AD [87]. ADAM-10 is the major constitutive α-secretase for APP processing [88,
89]. To date, platelet ADAM10 (a disintegrin and metalloprotease) has been reported to be
significantly reduced in platelets in AD [85, 90, 91] while others failed to detect changes in
alpha- and beta-secretase activities in AD [92]. Moreover, reduction in ADAM-10 levels
correlates with the progression and seems to be stage-dependent [91].
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References Effects on secretases
Johnston et al., 2008 ↑  platelet membrane ß-secretase activity in AD comparedto controls;
Colciaghi et al., 2002, 2004
↓  ADAM10 in AD compared to controls
↓  level of alpha APPs
↑  BACE1 in AD
Tang et al., 2006 ↑  BACE1 in AD↓  ADAM10 in AD
Gorham et al., 2010 unchanged alpha- and beta-secretase activities and -ratioin AD and MCI
Decourt et al., 2013 ↓  BACE1 in AD (newly developed ELISA)
Manzine et al., 2013 ↓  ADAM10 in AD
Table 7. Platelet secretase activity in AD
4.3. Activation of platelets by beta-amyloid
It is well known that different heterogeneous amyloidogenic peptides (Aβ(1-40), Aβ(1-42),
Aβ(25-36)) as well as aggregated Aβ can induce platelet aggregation [15, 16]. Platelets store
and release preferentially the 40 amino acid Aβ fragment in their granules upon stimulation
with physiological agonists like thrombin, collagen or calcium ionophores [93, 61, 94, 95]. Once
released, Aβ peptides trigger platelet activation, initiating a vicious feedback loop of platelet
activation and Aβ release. Further, apoptotic stimuli significantly increase platelet Aβ(40) but
not Aβ(42) suggesting that this pathway determines altered APP processing [96, 97]. Recently
it was shown that Aβ induces platelet activation independent of known physiological agonists
[16]. It was furthermore suggested that platelets modulate aggregation of soluble Aβ into
fibrillar Aβ and facilitate platelet adhesion at vascular Aβ accumulations, contributing to the
full occlusion of the affected vessel [18]. At this point it seems therefore likely that platelets
and platelet-derived Aβ may contribute to a significant degree to the amyloid burden in the
vascular walls promoting CAA in AD patients [96].
5. Oxidative stress, radicals and mitochondrial pathologies
Excessive chronic oxidative stress and production of radicals in the AD brain has been
considered to promote cellular degeneration. Especially, nitric oxide (NO) and peroxynitrite
(ONOO) are very reactive toxic radicals (ROS). It becomes more and more clear that a dysre‐
gulation of mitochondria and the involvement of cytochrome C-oxidase may play a role in this
process. Vascular damage and endothelial dysfunction may play a role in AD and platelets
serve as a source of oxidative stress. Mitochondria are the major sites responsible for more
than 90 % of the ROS generation. In AD, mitochondrial DNA of cortical neurons was reported
to induce excessive oxidative damage and increased DNA mutations [98-100]. Moreover,
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abnormal mitochondrial size and decreased mitochondrial number in AD and MCI are likely
to increase ROS generation and oxidative damage [99, 101]. In platelets reduced Complex IV
and Complex III activity has been repeatedly associated with AD [102-105, 32]. Subsequently,
Aβ was shown to interact directly with mitochondria and inhibit platelet Complex IV activity
inducing oxidative stress [106].
5.1. Nitric oxide and peroxynitrite
An increase in nitric oxide synthase (NOS) has been associated with normal aging and with
AD [107, 108, 33]. Similarly to NO, peroxynitrite (ONOO) was found to be increased in AD
patients and both NO and ONOO are linked to reduced Na+/K+-ATPase activity in platelet
membranes of AD patients [108]. Additionally, carriers of the epsilon 4 allele of apolipoprotein
E (APOE) show higher NOS compared to non-carriers [109]. In contrast, others found signif‐
icantly lower NO concentrations in platelets of AD patients and a generally higher platelet
aggregation rate. Since NO is known to inhibit platelet aggregation, NO might be responsible
for the aggregation of platelets in the observed AD cohort [110].
References Effects on nitric oxide
Kawamoto et al., 2005 ↑  NO and peroxynitrite in AD
Vignini et al., 2007, 2013; ↑  NO and ONOO(-) peroxynitrite in AD
Marcourakis et al., 2008 ↑  NOS activity in APOE epsilon 4 carriers
Yu and Jia, 2009 ↓  NO and eNOS (endothelial nitric oxide synthase)
Table 8. Platelet nitric oxide and peroxynitrite concentrations in AD
5.2. Cytochrome c oxidase
Cytochrome C oxidase (COX) is an enzyme located in mitochondria and may play a role in the
production of radicals. In most studies, reduced platelet COX activity has been found in AD
[111-113, 102, 103, 32, 104] but also in cognitively normal individuals with a maternal history
of AD [114]. However, another study did not find any differences in COX activity in AD [115].
Recently, reduced mitochondrial COX activity has been found, which correlates to decreased
mitochondrial membrane potential, resulting in higher lipid peroxides, superoxide radicals
and protein carbonyls [111]. It has been proposed, that reduced COX activity causes higher
tissue vulnerability and reduced oxygen availability [104].
5.3. Monoamino-oxidase B
Monoamino-oxidase-B (MAO-B) is an important enzyme located in the mitochondria and
plays a role in metabolic processes of serotonin. Studies on platelet MAO-B activity yielded
inconsistent results up to date: increased MAO-B activity was reported by several groups
[116-126], while few researchers could not find any abnormalities [127,128]. The decline of
mini-mental state examination scores (MMSE) preceded the elevation of MAO-B activity
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[116-119]. It has been suggested that MAO-B activity might be an indicator for severity and
clinical progress in AD [57]. In another study, non-psychotic AD patients showed significantly
higher platelet MAO-B activity, suggesting that MAO-B activity can differentiate between
psychotic and non-psychotic subtypes of AD [56].
References Effects on MAO-B activity
Zellner et al., 2012 ↑  MAO-B activity correlated with ↑  MAO-B proteinexpression in AD
Mimica et al., 2008 ↑  in AD in non-psychotic patients
Soto et al., 1999 ↑  22% MAO-B activity in AD
Götz et al., 1998 ↑  MAO-B activity in AD
Bongioanni et al., 1996 ↑  MAO-B activity in AD
Ahlskop et al.,1996 unchanged
Konings et al., 1995 unchanged
Parnetti et al., 1992, 1994 ↑  MAO-B activity in LOAD compared to controls andEOAD
Regland et al., 1991 ↑  MAO-B activity in AD; after B12 therapy MAO-Bactivity was reduced to a normal level
Schneider et al., 1988 ↑  MAO-B activity in female AD without agitation anddelusions
Danielczyk et al., 1988 ↑  MAO-B activity in AD (non-familial)
Alexopoulos et al., 1987 ↑  MAO-B activity in demented patients with and withoutdepression
Adolfsson et al., 1980 ↑  MAO-B activity in AD
Table 10. Platelet MAO-B activity in AD
References Effects on COX activity
Silva et al., 2013 ↓  COX, mitochondrial membrane potential , cytochrome c content
Burbaeva et al., 2012 ↓  COX in AD and MCI
Mosconi et al., 2011 ↓  COX activity in cognitively normal individuals with a history ofmaternal LOAD
Cardoso et al., 2004 ↓  15 % COX activity in AD despite COX subunits were present atnormal levels
Bosetti et al., 2002 ↓  COX in AD and MCI
Van Zuylen et al., 1992 unchanged
Parker et al., 1990, 1991, 1994 ↓  COX in AD
Table 9. Platelet COX activity in AD
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6. Changes of other biological systems
6.1. GSK3β activity
Glycogen synthase kinase 3-beta (GSK3β) is involved in the regulation of glycogen synthesis
by phosphorylating and inactivating the glycogen synthase and in the regulation of intracel‐
lular signalling pathways [129-131]. Moreover, in neural cell tissues GSK3β is the most
important Tau kinase and has been linked to synaptic plasticity and neural injury [132, 133].
Therefore, deregulation of GSK3β has a significant impact on the formation of neurofibrillary
tangles. GSK3β is also expressed in platelets and might be involved in platelet activation [134].
A substantial higher expression of GSK3β has been shown in AD and MCI platelets as
compared to healthy controls, which also correlated with worse memory performance [135].
6.2. Phospholipase activity
It is known that AD is associated with chronic inflammatory responses and platelets express
inflammatory mediators such as chemokines, interleukins, adhesive proteins and contain
enzymes such as phospholipase-A2 (PLA2) [20]. Phospholipases are important platelet
enzymes involved in the metabolism of membrane phospholipids and inflammatory synthesis.
PLA2 and phospholipase C (PLC) are altered in peripheral blood cells and significantly
decreased PLC activity in platelets of AD patients has been reported [136], suggesting aberrant
phospholipase metabolism. Further, decreased PLA2 activity was found in human platelets
[137, 138], which correlates with the degree of cognitive impairment and is modulated by
cognitive training in healthy elders [139]. In contrast, an increased platelet PLA2 activity in
individuals with AD has also been shown [140]. Thus, again the reports on these enzyme
activities are very controversial and do not allow to establish a concluding interpretation.
References Effects on PLA2 and PLC activity
Krzystanek et al., 2007 ↑  PLA2 in AD
Gattaz et al., 1995, 1996, 2004 ↓  PLA2 in AD and MCI
Matushima et al., 1995, 1998 ↓  PLC in AD
Table 11. Platelet PLA2 and PLC activity in AD
6.3. Overview of other platelet components found to be altered in AD
Several other biological systems have been studied in platelets of AD patients, such as e.g.
decreased plasma antioxidant power levels [107], decreased cathepsin D [141], increased
platelet glutamine synthetase-like protein level in MCI [112], increased NA,K-ATPase
activities in AD [107], unchanged Vitamin E and cholesterol content between AD and controls
[32] or increased phenolsulphotransferase activity in demented patients [142] or decreased
platelet peripheral-type benzodiazepine binding [143]. However, we do not claim to provide
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a complete overview of all markers. Anyhow, none of these markers has been found to be a
suitable reproducible marker for AD.
7. Platelets as biomarkers
Biomarkers must objectively reflect physiological processes linked to AD and should be
globally reproducible with easy-to-perform tests [144]. Moreover, besides being sensitive
enough to differentiate AD from clinically similar diseases, a good biomarker should be able
to detect early disease-associated changes. In AD, abnormal metabolism of APP, hyperphos‐
phorylation of Tau, induction of oxidative stress and inflammatory cascades result in patho‐
logical changes in liquid fluids. Currently, the laboratory diagnosis of AD is based on the
combination of three CSF biomarkers yielding a sensitivity of >95% and specificity of >85%
[145, 146]. However, considering the invasiveness of lumbar puncture and the growing
incidence rate of AD, the need for biomarkers in more accessible body fluids is necessary. Blood
measurements are minimally invasive and less time-consuming compared to CSF. The
establishment of new markers in plasma/serum has proven to be difficult because changes
mirror a broad spectrum of physiological processes not necessarily related to AD [144].
Moreover, changes in plasma/serum are very small and heterogeneous, thus making the search
for reliable and sensitive biomarkers challenging.
Within the search for peripheral biomarkers in AD, blood platelets have been of great interest
during the last decades. These anuclear blood cells share several homeostatic functions with
neurons such as accumulation and release of neurotransmitters like serotonin, and expression
of receptors and enzymes [147]. Moreover, human platelets have shown to be the most
important source of more than 90% of the circulating APP [148, 149]. On grounds of these
findings, platelets can be considered a valid peripheral model for the analysis of metabolic
pathways linked to AD. Despite great efforts, to date no specific platelet biomarker has been
successfully established, while some platelet components have shown to be of greater validity
than others.
Overall, the so far published studies underline the need to establish concurrent methods in
order to yield comparable results and avoid methodological diversity among institutes.
Platelets contain several types of surface receptors responding to external stimuli with
activation or inhibitory actions [150]. In response to physiological and non-physiological
stimuli, platelet granules and their contents are released, thus requiring careful handling
during isolation and experimentation in order to avoid activation. Effectively, different platelet
isolation and processing procedures may account to a significant extent for the observed inter-
rater differences between institutes. Moreover, different phases of the disease, comorbidities
or medications need to be taken into consideration when evaluating platelet status in AD
patients. Additionally, further analysis and classification of platelets with respect to their
different features (e.g. density fraction) might be helpful to generate more significant data.
Besides a homogeneous patient group, the selection of healthy, age-matched controls is a
known challenge in AD-research and might additionally explain varying data. Therefore, the
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so far obtained results need to be replicated in large and homogeneous cohorts according to
the same methodological protocol by independent researchers. To date, the use of platelet
biomarkers in the diagnostic routine of AD can yet not be recommended and is in urgent need
of final evaluation.
8. Conclusions
In conclusion, the search for platelet biomarker so far has highlighted some candidates worth
further investigation, while the breakthrough in identifying one satisfyingly specific and
sensitive marker has yet to be awaited. Overall, among the studied platelet components and
according to the available data, the platelet APP ratio and COX activity seem the most
promising candidates for establishing new peripheral biomarkers for AD.
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